ArticleViruses2026
Development of Cell Culture-Derived Hemagglutination Antigens for Japanese Encephalitis Virus Genotypes 1 and 3.
Article in Viruses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Conventional Japanese encephalitis virus (JEV) hemagglutination inhibition (HI) antigens are contingent on sucking mouse brain (SMB), and present ethical and standardization challenges. In this study, we established an alternative cell culture platform using LFBK cells to produce JEV genotype I (GI) and III (GIII) antigens. Viral replication and hemagglutination (HA) activity were evaluated in six cell lines. Although raw supernatants exhibited limited HA activity, 100-fold polyethylene glycol (PEG) 8000 concentration and binary ethylenimine (BEI) inactivation of LFBK cultures successfully resulted in high-titer antigens for the K95 (GI, 256 HAU), K87 (GIII, 64 HAU), and Nakayama (GIII, 1024 HAU) strains. Diagnostic validation with swine sera showed 100% concordance between the cell-derived Nakayama antigen and commercial SMB standard. Notably, cell-concentrated GI antigens (K95 and K87) demonstrated significantly higher sensitivity (
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.